Lung Cancer Drug Fails To Meet Endpoints
Ligand Pharmaceuticals' lung cancer drug, Targretin, didn't meet endpoints of improved overall survival in two Phase III studies.
Part of the
network
network
Tag: Phase III Trial
Phase III Avastin Study Results
Genentech and Roche announced that an interim analysis of a Phase III study of Avastin plus paclitaxel and carboplatin chemotherapies…
REVLIMID Trials Exceed Pre-Specified Value
Celgene announced that analyses of both Phase III Special Protocol Assessment (SPA) multiple myeloma trials exceeded the pre-specified value for…
